English

Turning Point Therapeutics, Inc.

EDGAR

TPTX Quarterly report (10-Q) · filed 2022-08-08

16 filing records in this dataset, filed from 2019-03-21 to 2022-08-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

119 thousand USD

2022 Q2 · USD

Exact inputs and evidence

Revenue: 119000 USD Source

Operating margin

-104,507.56%

2022 Q2 · %

Exact inputs and evidence

Operating Income: -124364000 USD Source
Revenue: 119000 USD Source

Operating cash flow

-105 million USD

2022 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -163629000 USD Source
Operating Cash Flow: -58331000 USD Source

Free cash flow

-107 million USD

2022 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -163629000 USD Source
Operating Cash Flow: -58331000 USD Source
Capital Expenditure: 1974000 USD Source
Capital Expenditure: 447000 USD Source

Cash and cash equivalents: 290 million USD 2022-06-30 Source
Exact value

290147000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 49.9 million shares 2022-06-30 Source
Exact value

49885036 shares

Reported share-count change

1.00% · 493 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

49391738 shares · 2021-06-30· Source
49885036 shares · 2022-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.01 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Revenue: 460000 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 30829000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 30829000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 429000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 119000 USD · 2022-04-01 – 2022-06-30 Source

Net income

-342 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Net income: -66325000 USD · 2021-07-01 – 2021-09-30 Source
Net income: -236551000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -158102000 USD · 2021-01-01 – 2021-09-30 Source
Net income: -74445000 USD · 2022-01-01 – 2022-03-31 Source
Net income: -123088000 USD · 2022-04-01 – 2022-06-30 Source

Operating cash flow

-259 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Operating cash flow: -99734000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -58069000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -153885000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -99734000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -58331000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -163629000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -58331000 USD · 2022-01-01 – 2022-03-31 Source

Capital expenditure

3.53 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Capital expenditure: 2040000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 874000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 2427000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 2040000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 447000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 1974000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 447000 USD · 2022-01-01 – 2022-03-31 Source

Free cash flow

-263 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Operating cash flow: -99734000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -58069000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -153885000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -99734000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -58331000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -163629000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -58331000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2040000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 874000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 2427000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 2040000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 447000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 1974000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 447000 USD · 2022-01-01 – 2022-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-08-08.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2021-12-31
Operating income: 5 of 11 periods available· newest 2021-12-31
Net income: 5 of 11 periods available· newest 2021-12-31
Operating cash flow: 5 of 11 periods available· newest 2021-12-31
Capital expenditure: 5 of 11 periods available· newest 2021-12-31
Total assets: 2 of 11 periods available· newest 2021-12-31
liabilities: No compatible figures in this window
Current assets: 2 of 11 periods available· newest 2021-12-31
Current liabilities: 2 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2021-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+23.3%

Prior period

USD 25 million

2020-01-01 – 2020-12-31
Current period

USD 30.83 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

30829000 − 25000000 = 5829000 USD

25000000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
30829000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Year-over-year change in Revenue: 5829000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 30829000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#1841663 Filing: 000095017022002302 Input fundies:Revenue: 25000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#1843513 Filing: 000095017022002302
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 79.26 million

Prior period

−USD 157.29 million

2020-01-01 – 2020-12-31
Current period

−USD 236.55 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-236551000 − -157292000 = -79259000 USD

-157292000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-236551000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Year-over-year change in Net income: -79259000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -236551000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2253401 Filing: 000095017022002302 Input fundies:NetIncome: -157292000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2255423 Filing: 000095017022002302
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 71.09 million

Prior period

−USD 82.79 million

2020-01-01 – 2020-12-31
Current period

−USD 153.89 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-153885000 − -82793000 = -71092000 USD

-82793000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-153885000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Year-over-year change in Operating cash flow: -71092000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -153885000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2315228 Filing: 000095017022002302 Input fundies:OperatingCashFlow: -82793000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2317238 Filing: 000095017022002302
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+92%

Prior period

USD 1.26 million

2020-01-01 – 2020-12-31
Current period

USD 2.43 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

2427000 − 1264000 = 1163000 USD

1264000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
2427000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Year-over-year change in Capital expenditure: 1163000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2427000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2341429 Filing: 000095017022002302 Input fundies:CapitalExpenditure: 1264000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2343563 Filing: 000095017022002302
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 30.83 million 100% of revenue
Operating costs Derived USD 268.83 million 872% of revenue
Operating income −USD 238 million −772% of revenue
Tax, interest and other Derived −USD 1.45 million −4.7% of revenue
Net income −USD 236.55 million −767% of revenue

Cash

Operating cash flow −USD 153.89 million −499% of revenue
Capital expenditure USD 2.43 million 7.9% of revenue
Free cash flow Derived −USD 156.31 million −507% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 747% of revenue.
2021 Operating loss: operating costs were 872% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	25000000	186836000 Derived	-161836000	-4544000 Derived	-157292000	-84057000 Derived	Source 2020-01-01 – 2020-12-31: 25000000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -161836000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -157292000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -82793000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1264000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	30829000	268829000 Derived	-238000000	-1449000 Derived	-236551000	-156312000 Derived	Source 2021-01-01 – 2021-12-31: 30829000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -238000000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -236551000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -153885000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2427000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 30.8M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	25000000	Revenue: 25000000 Open source
20212021-12-31	Revenue	30829000	Revenue: 30829000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

23.3% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 25000000 Open source
20212021-12-31	Year over year	23.3%	Revenue: 30829000 Open source Revenue: 25000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -772% 2021

Net margin -767.3% 2021

Free cash flow margin -507% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-647.3%	Operating Income: -161836000 Open source Revenue: 25000000 Open source
20212021-12-31	Operating margin	-772%	Operating Income: -238000000 Open source Revenue: 30829000 Open source
20202020-12-31	Net margin	-629.2%	Net Income: -157292000 Open source Revenue: 25000000 Open source
20212021-12-31	Net margin	-767.3%	Net Income: -236551000 Open source Revenue: 30829000 Open source
20202020-12-31	Free cash flow margin	-336.2%	Revenue: 25000000 Open source Operating Cash Flow: -82793000 Open source Capital Expenditure: 1264000 Open source
20212021-12-31	Free cash flow margin	-507%	Revenue: 30829000 Open source Operating Cash Flow: -153885000 Open source Capital Expenditure: 2427000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -153.9M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-82793000	Operating Cash Flow: -82793000 Open source
20212021-12-31	Operating cash flow	-153885000	Operating Cash Flow: -153885000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -156.3M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-84057000	Operating Cash Flow: -82793000 Open source Capital Expenditure: 1264000 Open source
20212021-12-31	Free cash flow	-156312000	Operating Cash Flow: -153885000 Open source Capital Expenditure: 2427000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Liabilities / assets	Not reported	Total Assets: 1136713000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 1003463000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

21.08× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	46.35×	Current Assets: 1130679000 Open source Current Liabilities: 24392000 Open source
20212021-12-31	Current assets / current liabilities	21.08×	Current Assets: 992462000 Open source Current Liabilities: 47089000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 16.59 million Exact value Exact value: -16593000 USD 2017-01-01 – 2017-12-31: -16593000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Turning Point Therapeutics, Inc. · 2017-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Net Income: -16593000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16593000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459020011492/tptx-20191231.xml#87763 Filing: 000156459020011492 The citation records this snapshot. The page link may show a newer release later.	−USD 12.64 million Exact value Exact value: -12640000 USD 2017-01-01 – 2017-12-31: -12640000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Turning Point Therapeutics, Inc. · 2017-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Operating Cash Flow: -12640000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12640000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459020011492/tptx-20191231.xml#111485 Filing: 000156459020011492 The citation records this snapshot. The page link may show a newer release later.	USD 88,000 Exact value Exact value: 88000 USD 2017-01-01 – 2017-12-31: 88000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Turning Point Therapeutics, Inc. · 2017-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Capital Expenditure: 88000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 88000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459020011492/tptx-20191231.xml#112543 Filing: 000156459020011492 The citation records this snapshot. The page link may show a newer release later.	−USD 12.73 million Calculation and evidence -12640000 − 88000 USD Exact free cash flow: -12728000 USD 2017-01-01 – 2017-12-31: -12640000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 88000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Turning Point Therapeutics, Inc. · 2017-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Free cash flow: -12728000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12640000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459020011492/tptx-20191231.xml#111485 Filing: 000156459020011492 Input fundies:CapitalExpenditure: 88000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459020011492/tptx-20191231.xml#112543 Filing: 000156459020011492 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 24.79 million Exact value Exact value: -24785000 USD 2018-01-01 – 2018-12-31: -24785000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Turning Point Therapeutics, Inc. · 2018-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Net Income: -24785000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24785000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459021009849/tptx-10k_20201231.htm#2408526 Filing: 000156459021009849 The citation records this snapshot. The page link may show a newer release later.	−USD 23.53 million Exact value Exact value: -23533000 USD 2018-01-01 – 2018-12-31: -23533000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Turning Point Therapeutics, Inc. · 2018-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Operating Cash Flow: -23533000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23533000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459021009849/tptx-10k_20201231.htm#2470462 Filing: 000156459021009849 The citation records this snapshot. The page link may show a newer release later.	USD 302,000 Exact value Exact value: 302000 USD 2018-01-01 – 2018-12-31: 302000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Turning Point Therapeutics, Inc. · 2018-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Capital Expenditure: 302000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 302000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459021009849/tptx-10k_20201231.htm#2497702 Filing: 000156459021009849 The citation records this snapshot. The page link may show a newer release later.	−USD 23.84 million Calculation and evidence -23533000 − 302000 USD Exact free cash flow: -23835000 USD 2018-01-01 – 2018-12-31: -23533000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 302000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Turning Point Therapeutics, Inc. · 2018-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Free cash flow: -23835000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23533000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459021009849/tptx-10k_20201231.htm#2470462 Filing: 000156459021009849 Input fundies:CapitalExpenditure: 302000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000156459021009849/tptx-10k_20201231.htm#2497702 Filing: 000156459021009849 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 72.13 million Exact value Exact value: -72131000 USD 2019-01-01 – 2019-12-31: -72131000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Turning Point Therapeutics, Inc. · 2019-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Net Income: -72131000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -72131000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2257445 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	−USD 57.68 million Exact value Exact value: -57684000 USD 2019-01-01 – 2019-12-31: -57684000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Turning Point Therapeutics, Inc. · 2019-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Operating Cash Flow: -57684000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57684000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2319247 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	USD 1.74 million Exact value Exact value: 1744000 USD 2019-01-01 – 2019-12-31: 1744000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Turning Point Therapeutics, Inc. · 2019-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Capital Expenditure: 1744000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1744000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2345697 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	−USD 59.43 million Calculation and evidence -57684000 − 1744000 USD Exact free cash flow: -59428000 USD 2019-01-01 – 2019-12-31: -57684000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1744000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Turning Point Therapeutics, Inc. · 2019-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Free cash flow: -59428000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57684000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2319247 Filing: 000095017022002302 Input fundies:CapitalExpenditure: 1744000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2345697 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 157.29 million Exact value Exact value: -157292000 USD 2020-01-01 – 2020-12-31: -157292000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Turning Point Therapeutics, Inc. · 2020-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Net Income: -157292000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -157292000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2255423 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	−USD 82.79 million Exact value Exact value: -82793000 USD 2020-01-01 – 2020-12-31: -82793000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Turning Point Therapeutics, Inc. · 2020-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Operating Cash Flow: -82793000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -82793000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2317238 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	USD 1.26 million Exact value Exact value: 1264000 USD 2020-01-01 – 2020-12-31: 1264000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Turning Point Therapeutics, Inc. · 2020-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Capital Expenditure: 1264000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1264000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2343563 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	−USD 84.06 million Calculation and evidence -82793000 − 1264000 USD Exact free cash flow: -84057000 USD 2020-01-01 – 2020-12-31: -82793000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1264000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Turning Point Therapeutics, Inc. · 2020-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Free cash flow: -84057000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -82793000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2317238 Filing: 000095017022002302 Input fundies:CapitalExpenditure: 1264000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2343563 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 236.55 million Exact value Exact value: -236551000 USD 2021-01-01 – 2021-12-31: -236551000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Net Income: -236551000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -236551000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2253401 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	−USD 153.89 million Exact value Exact value: -153885000 USD 2021-01-01 – 2021-12-31: -153885000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Operating Cash Flow: -153885000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -153885000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2315228 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	USD 2.43 million Exact value Exact value: 2427000 USD 2021-01-01 – 2021-12-31: 2427000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Capital Expenditure: 2427000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2427000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2341429 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.	−USD 156.31 million Calculation and evidence -153885000 − 2427000 USD Exact free cash flow: -156312000 USD 2021-01-01 – 2021-12-31: -153885000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2427000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Turning Point Therapeutics, Inc. · 2021-12-31 Turning Point Therapeutics, Inc. (edgar:1595893) Free cash flow: -156312000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:45:05Z Snapshot: 9fcc2f0519851730d49cc16073aa6fe089f958a02f14613a0a303f36335415ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1595893?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -153885000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2315228 Filing: 000095017022002302 Input fundies:CapitalExpenditure: 2427000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1595893/000095017022002302/tptx-20211231.htm#2341429 Filing: 000095017022002302 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

16 filings · 818 latest values · 818 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001595893, 1595893, TPTX, edgar:1595893

Also known as TP Therapeutics, INC, TP Therapeutics, Inc., Turning Point Therapeutics, Inc.

Turning Point Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation